CYKLOKAPRON 500 MG 500 MG
TRANEXAMIC ACID : 500 MG · DIN 02064405 · PFIZER CANADA ULC
Health Canada status: MARKETED
What is CYKLOKAPRON 500 MG?
CYKLOKAPRON 500 MG 500 MG contains TRANEXAMIC ACID : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02064405, held by PFIZER CANADA ULC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 08-Jul-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CYKLOKAPRON 500 MG used for?
CYKLOKAPRON® (tranexamic acid) is indicated for: Hereditary angioneurotic oedema. Increased local fibrinolysis when the diagnosis is indicative of hyperfibrinolysis, as with conization of the cervix, dental extraction in patients with coagulopathies (in conjunction with antihaemophilic factor) epistaxis, hyphaema, and menorrhagia (hypermenorrhea).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02064405 |
|---|---|
| Brand name | CYKLOKAPRON 500 MG |
| Generic / active ingredient | TRANEXAMIC ACID : 500 MG |
| Manufacturer | PFIZER CANADA ULC |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | B02AA02 TRANEXAMIC ACID |
| AHFS class | 20:28.16 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 08-Jul-2005 |
| Original market date | 1995-12-31 00:00:00 |
How is it stored and handled?
The mixture should be used immediately after preparation. If storage is necessary, the mixture should be stored at 2 – 8oC for a maximum of 24 hours. Mixture not used within 24 hours of preparation, should be discarded.
How is it supplied?
Oral Tablet: Bottles of 100; Ampoules: 10 x 5 mL and 10 x 10 mL
Is TRANEXAMIC ACID in shortage in Canada?
A Canadian shortage report is on file for this molecule: Resolved — reported by SANDOZ CANADA INCORPORATED, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code B02AA02 TRANEXAMIC ACID. 12 of 23 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CYKLOKAPRON 100 MG/ML | 100 MG | SOLUTION | PFIZER CANADA ULC | MARKETED | DIN 02064413 |
| GD-TRANEXAMIC ACID | 500 MG | TABLET | GENMED A DIVISION OF PFIZER CANADA ULC | MARKETED | DIN 02409097 |
| M-TRANEXAMIC ACID | 500 MG | TABLET | MANTRA PHARMA INC | MARKETED | DIN 02549395 |
| MAR-TRANEXAMIC ACID | 500 MG | TABLET | MARCAN PHARMACEUTICALS INC | MARKETED | DIN 02496232 |
| TRANEXAMIC ACID | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02519194 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | JAMP PHARMA CORPORATION | MARKETED | DIN 02497328 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | AURO PHARMA INC | MARKETED | DIN 02466015 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | EUGIA PHARMA INC. | MARKETED | DIN 02531194 |
| TRANEXAMIC ACID INJECTION | 100 MG | SOLUTION | OMEGA LABORATORIES LIMITED | MARKETED | DIN 02392763 |
| TRANEXAMIC ACID INJECTION BP | 100 MG | SOLUTION | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02246365 |
Who else supplies TRANEXAMIC ACID worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TRANEXAMIC ACID appears in 81 registered pack listings across 8 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.